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Abstract
Regulation of myosin light chain phosphatase (MLCP) via protein kinase C (PKC) and the 17 kDa PKC-potentiated inhibitor of
myosin light chain phosphatase (CPI-17) has been reported as a Ca2+ sensitization signaling pathway in smooth muscle
(SM), and thus may be involved in tonic vs. phasic contractions. This study examined the protein expression and spatial-
temporal distribution of PKCa and CPI-17 in intact SM tissues. KCl or carbachol (CCh) stimulation of tonic stomach fundus
SM generates a sustained contraction while the phasic stomach antrum generates a transient contraction. In addition, the
tonic fundus generates greater relative force than phasic antrum with 1 mM phorbol 12, 13-dibutyrate (PDBu) stimulation
which is reported to activate the PKCa – CPI-17 pathway. Western blot analyses demonstrated that this contractile
difference was not caused by a difference in the protein expression of PKCa or CPI-17 between these two tissues.
Immunohistochemical results show that the distribution of PKCa in the longitudinal and circular layers of the fundus and
antrum do not differ, being predominantly localized near the SM cell plasma membrane. Stimulation of either tissue with
1 mM PDBu or 1 mM CCh does not alter this peripheral PKCa distribution. There are no differences between these two
tissues for the CPI-17 distribution, but unlike the PKCa distribution, CPI-17 appears to be diffusely distributed throughout
the cytoplasm under relaxed tissue conditions but shifts to a primarily peripheral distribution at the plasma membrane with
stimulation of the tissues with 1 mM PDBu or 1 mM CCh. Results from double labeling show that neither PKCa nor CPI-17 co-
localize at the adherens junction (vinculin/talin) at the membrane but they do co-localize with each other and with caveoli
(caveolin) at the membrane. This lack of difference suggests that the PKCa - CPI-17 pathway is not responsible for the tonic
vs. phasic contractions observed in stomach fundus and antrum.
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Introduction
The mechanism(s) determining tonic (sustained) vs. phasic
(transient) smooth muscle (SM) contractions remains unresolved.
Diverse innervation and circulating signaling molecules in addition
to unique receptor and protein (isoform) expression and intracel-
lular signaling pathways complicate the issue. Not unexpectedly,
there are multiple proposed hypotheses to explain tonic force
maintenance in SM including: slowly- or non-cycling smooth
muscle myosin cross-bridges called latch bridges [1,2,3,4];
recruitment of non-muscle myosin II [5,6,7]; formation of
caldesmon or calponin dependent actin-to-myosin cross-links
[8,9]; formation of cytoskeletal force-bearing structures
[10,11,12]; and regulation of myosin LC20 phosphorylation via
second messenger pathways affecting myosin light chain kinase
(MLCK) and myosin light chain phosphatase (MLCP) activity
[13,14,15,16,17,18]. This last category is of interest because of the
reported differential expression, localization and regulation of
these second messenger proteins in various SM tissues. Variable
regulation of MLCK and MLCP activity could provide not only a
means for Ca2+ sensitization, but also a possible mechanism for
tonic vs. phasic contraction. Inactivation of MLCP via the PKCa
–CPI-17 pathway would allow for maintained high myosin light
chain (MLC20) phosphorylation and thus a sustained contractile
force. A failure to inactivate MLCP would reduce MLC20
phosphorylation and force, resulting in a transient contraction.
Stomach fundus SM generates a tonic (sustained) contraction
while stomach antrum SM generates a phasic (transient) contrac-
tion in response to a variety of stimuli.
Ca2+ sensitization, which involves the activation of G-protein-
coupled second messenger pathways that sensitize the contractile
proteins to [Ca2+i] by inhibiting MLCP, can occur by any of
numerous pathways. One of the reported pathways for
inhibition of MLCP activity includes the protein kinase C/C-
kinase activated PP1 inhibitor protein of 17 kDa (PKC/CPI-17)
pathway [19,20]. G-coupled protein receptor (GCPR) activation
resulting in activation of phospholipase C (PLC), hydrolyzes
phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG is
known to activate PKC which can cause phosphorylation of
CPI-17 to selectively inhibit MLCP (reviewed for visceral SM in
[17]). PKC is believed to be regulated by its activation and
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spatial distribution within the cell, the latter being controlled by
anchoring proteins that bind to and restrict the location of PKC
to specific regions of the cell [21,22]. For example, reports of
constitutively active L-type Ca2+ channels and their regulation
by PKC [23,24] suggests that PKC is localized near the
membrane in smooth muscle cells. The cellular function of CPI-
17 in the cell could vary depending on its level of protein
expression and whether it is located near the plasma membrane
where PKCa is located/activated, or associated with the
contractile myosin thick filaments where MLCP would be
located to de-phosphorylate myosin light chain 20 (MLC20).
The expression of PKCa and CPI-17 and their spatial-temporal
re-distribution upon tissue activation have been proposed in Ca2+
sensitization of smooth muscle tissues (for review [14,15,16,17]).
Thus it is possible that differences in their expression and cellular
localization/translocation could be involved in determining tonic
vs. phasic contractile responses. For these two proteins to be part
of a pathway involved in inhibiting MLCP activity during tissue
activation, and thus causing a tonic or phasic response, they need
to be expressed at appropriate levels and positioned at the correct
location in the cell at the correct time. Because PKC is activated
by DAG (a membrane bound phospholipid), it must also be at the
membrane at least temporally for this to happen. And if CPI-17 is
going to inhibit the MLCP from dephosphorylating MLC20 on the
thick filaments, CPI-17 at some point needs to be in the cytosol
associated with the thick filaments present there. With these two
steps occurring in two spatially distinct regions of the cell, one or
both of these proteins has to translocate to the other region for
them to interact and complete the pathway.
The purpose of this study was to test the hypothesis that the
PKCa - CPI-17 Ca2+ sensitization pathway is involved in
determining tonic (sustained) and phasic (transient) contractile
responses in smooth muscles. To do this we determined the
protein expression and spatial-temporal distribution of PKCa
and CPI-17 in the phasic stomach antrum and tonic stomach
fundus under relaxed and activated conditions. The results
showing no significant difference in expression of either of these
two proteins, nor in their peripheral distribution between these
two tissues are inconsistent with the hypothesis that the PKCa-
CPI-17 Ca2+ sensitization pathway is the determining factor for
the tonic vs. phasic contractile responses observed in these
tissues.
Methods
Organ and Tissue Handling
Swine tissues (stomachs) were obtained from Hansen Meat
Service (Franksville, WI) and put in cold physiological salt solution
(PSS; (in mM): 140.1 NaCl, 4.7 KCl, 1.2 Na2HPO4, 2.0 MOPS
(pH 7.4), 0.02 Na2EDTA, 1.2 MgSO4, 1.6 CaCl2, and 5.6
glucose). Stomachs were cleaned of blood, loose connective tissue,
and in some cases, the mucosa, and frozen immediately or stored
in PSS in the refrigerator for 0–2 days. Some organs were fresh
frozen as soon as possible following post-mortem (60–90 minutes).
Some organs were incubated in PSS and/or stimulated with
1.0 mM CCh or PDBu (Sigma) at 37uC for different time points
prior to freezing. Variable incubation times and agonist concen-
trations were also tested. For immunohistochemistry all tissue was
stored frozen until sectioned and immunoreacted. Freezing in all
cases involved placing pieces of tissues or tissue strips in isopentane
cooled in liquid nitrogen followed by storage at 280uC. Five to six
mm sections of the frozen tissues were cut on a Leica CM1900
cryostat, picked up on glass slides and stored frozen (0–1 days)
until immunoreacted.
Immunoreactions and Reagents
The antibodies used were obtained from the following sources:
PKCa (H-7 and C-20) and CPI-17(H-60) from Santa Cruz
Biotech, Santa Cruz CA; Vinculin and Talin from Sigma, Saint
Louis, Missouri; Caveolin 1 from BD Biosciences, San Jose, CA;
Cy2 and Cy3 Donkey anti mouse or rabbit secondary’s from
Jackson ImmunoResearch, West Grove, PA; Alexa Fluor 594-
phalloidin and DAPI from Molecular Probes, Eugene, OR. All of
these antibodies have been used previously in our laboratory for
immunohistochemistry and western blotting where they show
specificity for a band of the correct molecular weight for the
respective protein indicated [25,26,27]. Negative controls where
the primary antibody is not included show no reactivity for these
bands and no immunofluorescence on tissue sections.
Frozen tissue sections picked up on glass slides were thawed at
room temperature and then fixed with 2% paraformaldehyde for
10 minutes, permeabilized in 0.5% Triton X-100 for 10 minutes
and blocked with 5 mg/ml BSA for 1 hour prior to reacting with
the primary antibody overnight (4uC) and then the appropriate
secondary antibody for one hour at room temperature. After the
secondary antibody, the tissues were incubated with DAPI
(0.5 mM), phalloidin (10–50 nM) or DAPI/phalloidin as appro-
priate for staining nuclei and/or filamentous actin. Multiple
washes were used following the primary and secondary incuba-
tions, and the counterstaining. Cover glasses were mounted using
buffered 75% glycerol with 0.2% n-propyl gallate to minimize
fading. All immunoreacting solutions were made in PBS-Tween
[(in g/liter: NaCl 8.0, KH2PO4 0.2, Na2HPO4 1.15, KCl 0.2,),
1% tween-20, pH 7.4] with 0.1% BSA. Negative controls included
0.1%BSA without the primary antibody, and showed no
immunoreaction.
Microscopy
Sections were observed using an Olympus IX70 microscope
with epifluorescence illumination. Digital images were taken with
a 16 bit Princeton Instruments (Princeton, NJ) CCD camera,
controlled through a PCI board via IPLab for Windows on a PC
(Ver. 3.6, Scanalytics; Fairfax, VA). Images were taken using
either a 1006 (1.3 NA) or 606 (1.25 NA) oil lens or a 406
(0.9 NA) air lens and stored on the PC. Emission filters used were
405, 490 and 570 nm. Sections were also viewed using a Nikon
confocal microscope (Nikon A1 confocal Eclipse Ti). The
objectives used were 1006 (1.4 NA) oil lens at 425, 488 and
561 nm. Similar results were observed in immunofluorescence
distributions using these two different systems.
Image Analysis of Distribution of PKC/CPI-17 of Individual
Cells in Tissues
Profiles of fluorescence intensity were taken for individual cells
in transverse tissue sections. Sections were observed at low
magnification (10–20x) to avoid areas of apparent artifacts (tissue
folding, freeze damage, etc). In an artifact free area the
magnification was increased to 40–100x, and pictures were taken
at these higher magnifications. Three different areas within one
tissue section were chosen to take pictures. Z-stack series were
taken individually for each of the three color channels used. 1 mm
thick Z sections were taken, and 15–25 Z sections were taken for
each tissue section (figures S1 & S2 show Z-stack examples of CPI-
17 immunoreactivity in antrum with and without tissue activation).
Each Z stack series was examined for each section to identify the
center z image, and this image was converted to a.bmp file, which
was imported to NIS-Elements AR 3.0 (Nikon) on a PC to analyze
the data.
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Profiles of PKCa and Phalloidin fluorescence intensity were
obtained for individual cells in transverse tissue sections. A line was
drawn across the center of the image field. Ten cells crossed by the
line were selected for measurements. Based on our previous
protocols [25], the first five pixels (,0.7 mm) on either side of the
cell where the phalloidin intensity increased sharply from baseline
were defined as the periphery of the cell. For cytosolic
measurements, a line was placed at least 2 mm away from the
cell periphery. Intensity measurements were made using a region
of interest (ROI) roughly at the center of the cell (for cytosolic
measurements), or along the cell’s membrane (for peripheral
measurements). For consistency, the size of the ROI is kept
constant for the peripheral and cytosolic measurements. Cells in
the section with very small diameters (not able to measure cytosolic
ROI at least 2 mm from the periphery) or with nuclei present
(visible DAPI staining where spatial limitations and perinuclear
organelles could confound the distribution) were excluded from
analysis. For PKCa, the ratio of the average intensity of PKCa at
the periphery over the total PKCa intensity (sum of PKCa
intensity from ROI at periphery and ROI in cytosol) was used.
Ten cells per field and three different fields were subjected to
measurement for data analysis for each tissue region, i.e. thirty
cells were counted and averaged for each sample (n = 1). The final
sample size was n= 5.The same procedures were applied to
measure the intensity of CPI-17, except that only one field of 10
cells were used for each sample (n = 1), with a final sample size of
n = 3.
Mechanical Measurements
Immediately before use, tissue strips were cut and clamped on
each end, with the clamps secured between hooks on a stationary
metal rod and an isometric force transducer (Harvard Apparatus,
Holliston, MA), in PSS bubbled with 95% O2/5% CO2 in water-
jacketed muscle chambers (Radnoti Glass Technology, Monrovia,
CA) at 37uC. The length of each strip was varied by repositioning
the stationary metal rod.
Smooth muscle tissue strips (stomach antrum and fundus) were
equilibrated for 1 h and stretched to a passive tension approxi-
mating Lo using an abbreviated length-tension curve. To contract
tissues, PSS was replaced with K+-PSS (109 mM KCl is
substituted iso-osmotically for NaCl) [28]. The muscle strips were
activated repeatedly with stretching of the tissue between each
activation, until peak force no longer showed a significant increase
over the previous contraction. Chambers were flushed three times
with PSS following each tissue activation. At least two repeatable
successive K+-PSS contractions were used to get a standard force
trace with a 10 minute rest between each contraction before
starting the experiment. The tissues were then activated with
1 mM carbachol and relaxed again, as was performed during K+-
PSS contractions. Subsequent contractions all included 1 mM
phentolamine and propranolol to block a- and b - adrenergic
receptors, respectively. Following the final 1 mM CCh contraction
and wash, the tissues were activated with 1 mM PDBu to record
their mechanical response.
Analysis of Force Data
Voltage signals from force transducers were digitized by
PowerLab 400 or 4 SP hardware (ADInstruments, Castle Hill,
Australia) visualized on a computer screen (Chart v3.6 or 4.0,
ADInstruments) as force (g) at 10 Hz and stored by software
command to a hard disk for later analyses. Figures were made with
the spreadsheet program Excel 2000 (Microsoft, Redmond, WA).
Gel Electrophoresis and Western Blotting
Protein expression was analyzed as described previously [29].
Tissues were homogenized at 50 mg/ml in 0.125 M Tris, 2%
sodium dodecylsulfate (wt/vol), 20% glycerol, 0.1% bromophenol
blue (wt/vol) and 20 mM dithiothreitol. Proteins were resolved on
low cross-linking sodium dodecylsulfate gels [30] and immuno-
blotting was performed as previously described [31]. The PKCa
antibody recognized either a single band or more frequently a
doublet at ,76 kD while the CPI-17 antibody recognized a single
band at ,17 kD. These sizes are consistent with the expected size
for these proteins based on gel mobility. To ensure accuracy of the
western blots, loading curves were done for both stomach fundus
and antrum samples over a 5-fold range of loadings (4–20 ml) for
actin (coomassie blue staining) and PKCa and CPI-17 (western
blotting). The results showed a linear relationship over this range
for all three proteins from both tissues (R2.0.98 for all results,
n = 3). Quantitation of PKCa and CPI-17 protein expression was
done on western blots using 5–10 ml loadings that was within this
linear range (n = 6).
Statistics
Statistical comparisons were carried out using MINITAB
(Minitab Inc. State College, PA). A one sample t-test was used
to test the distribution of PKCa/CPI-17 (a peripheral to total ROI
content of 0.5 indicates a ‘‘uniform’’ distribution in smooth muscle
cells (SMCs)) in antrum and fundus under resting condition. One
way ANOVA was performed to test for PKC/CPI-17 distribution
differences for the two tissues with different stimulating parame-
ters. Two sample t-tests were used to test the significance of
difference for expression level of PKCa or CPI-17 in antrum and
fundus. A two-tailed F-test for equality of two standard deviations
(SDs) determined a significantly lower SD in the ratio of caveolin
to PKCa when compared to the SD of the ratio of vinculin to
PKCa. A value of P,0.05 was considered significant for all
statistical tests. No statistical tests were done on the force data and
figure 1 is representative of similar data from 6 different animals.
Western blot data is from six animals. PKCa distribution data is
an average of thirty cells measured per animal and five animals
were tested. CPI-17 distribution data is an average of 10 cells
measured per animal and three animals were tested. Protein co-
localization data is based on a ‘n’ of at least 20 cells from at least 3
animals.
Results
Swine stomach fundus is a primarily tonic smooth muscle tissue
that responds to stimulation with a sustained contraction while the
antrum is a primarily phasic smooth muscle tissue that responds to
stimulation with a transient contraction (Fig. 1). In tissues these
responses are likely a result of direct stimulation of the smooth
muscle as addition of 1 mM propranolol (b agonist blocker) and
phentolamine (a agonist blocker) was used to prevent activation of
adrenergic receptors due to potential release of sympathetic
neurotransmitters. Stimulation of smooth muscle with PDBu is
used routinely to cause smooth muscle contraction via PKC
activation [32,33,34]. One mM PDBU causes a small slow
contraction in stomach fundus strips (,40% of K+ stimulation
response) while the antrum shows essentially no response (,5%
K+ stimulation) (Fig. 1). The difference between the sustained and
transient responses of these two tissues to KPSS and CCh, and the
presence or absence of a contractile response to PDBu stimulation
could be due to the expression and/or spatial-temporal distribu-
tion of the downstream second messengers (PKCa and CPI-17)
that are purported to be responsible for MLCP inhibition with
PKCa and CPI-17 Expression in Swine Stomach
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PDBu stimulation. To examine this we measured the expression
levels and determined the spatial-temporal distribution of PKCa
and CPI-17 in these tissues.
Figure 2 shows western blot results for the expression of CPI-17
and PKCa in the stomach antrum and fundus. Tissues were
processed controlling for protein concentration, and the results
were calculated based on the intensity of the respective protein
signal, and normalized to actin protein expression (Fig. 2). Both
methods (only normalized data shown) indicated that neither the
expression of CPI-17 protein nor that of PKCa protein is
significantly different (p.0.23 & p.0.28 respectively, n = 6) when
comparing these two SM tissues. Controls were done using a range
of loadings to confirm the range of linearity of loading, and that
samples used for quantitation were within this range (data not
shown, see methods). Because there are no differences in the
expression for these two proteins between these two tissues, we
next proceeded to determine if differences in their spatial-temporal
distribution could explain the difference in their responses to
PDBu stimulation.
Figure 3 show immuohistochemical results for the distribution
of PKCa in the longitudinal and circular layers of the fundus and
antrum. Under resting conditions in relaxing solution when there
is no force generation by the tissue, the PKCa appears to be
uniquely distributed preferentially near the periphery of the SMCs
(Fig. 3– green color, PSS). Stimulation of the tissues with 1 mM
CCh (39) or 1 mM PDBu (10 and 309) does not alter this peripheral
distribution of PKCa. The ratio of the distribution of the PKCa
near the plasma membrane relative to total cellular PKCa was
used to quantify possible changes in the distribution of this protein
under these different conditions. Figure 4 shows the results as the
ratio of the PKCa at the cell periphery relative to the total PKCa
present in the cell (peripheral/(peripheral+cytosol), see methods).
A ratio of 0.5 would indicate a ‘‘uniform’’ distribution of the
protein throughout the cell. The PKCa ratio (peripheral/total)
ranged from 0.64–0.68 in all the conditions examined. These
values are significantly greater than 0.5 (p,0.05), indicating that
PKCa is located primarily at the cell periphery (it is not
‘‘uniformly’’ distributed in the cell) and that this distribution does
not change between the relaxed or stimulated conditions.
Because PKCa is proposed to activate CPI-17, we proceeded to
determine the spatial-temporal distribution of CPI-17 in these
tissues under similar conditions. Figure 5 show immuohistochem-
ical results for the distribution of CPI-17 in the longitudinal and
circular layers of the fundus and antrum. Under resting conditions
in relaxing solution when there is no force generation by the tissue,
the CPI-17 appears to be diffusely distributed throughout the
SMCs (Fig. 5– PSS, fig. S1). Stimulation of the tissues with 1 mM
CCh (309) (but not 1 mM CCh for 39, data not shown) or 1 mM
PDBu (309) results in a significant change in this distribution such
that the CPI-17 now appears to be primarily at the periphery of
the cell in a distribution similar to that observed for PKCa (Fig. 5,
fig. S2). The ratio of the distribution of the CPI-17 near the plasma
membrane relative to total CPI-17 (peripheral+cytosolic) was used
to quantify possible changes in the distribution of this protein
under these different conditions. Figure 4 shows the results as the
ratio of peripheral-to-total CPI-17. The CPI-17 ratio (peripheral/
total) ranged from 0.49–0.67 in all tissues and conditions
examined. The ratio of CPI-17 peripheral/total in relaxed
conditions is not significantly different than 0.5 (means 0.49–0.5;
P.0.19) indicating that the CPI-17 is diffusely distributed
throughout the smooth muscle cells under this condition. This
does not change following 39 of 1 mM CCh stimulation as there is
still no significant difference from the relaxed conditions
(means = 0.53–0.55; P.0.05) with the exception of the fundus
tissues where the CPI-17 peripheral/total ratio is significantly
greater (p,0.05) at 39 (Fig. 4). With 309 of either 1 mM CCh or
1 mM PDBu stimulation, the CPI-17 distribution becomes
significantly greater than 0.5 for all tissues and layers
(means = 0.62–0.67, P,0.01), indicating that CPI-17 is now
located primarily at the cells periphery (it is no longer ‘‘uniformly’’
distributed throughout the cell), similar to the distribution of
PKCa (Fig. 4).
Figure 1. Force (normalized to peak force from KPSS stimulation) generated by stimulating with KPSS, 1 mM CCh, or 1 mM PDBu in
antrum (red) and fundus (blue). Antrum contractile response is not maintained during the stimulation while that in the fundus is. PDBu
generated a slow contraction in the fundus that is ,40% of its peak KPSS force, but caused little to no contraction in the antrum. Deflections in the
traces at the start of each wash are from changing the solution in the chambers. These are representative traces from 1 of 6 different animals used for
mechanical measurements.
doi:10.1371/journal.pone.0074608.g001
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The primarily peripheral distribution of PKCa (under both
relaxed and stimulated conditions) and CPI-17 (following 309
stimulation with CCh or PDBu) is not uniform at the cell
periphery, but punctate in distribution (Fig. 6). There is also a
punctate distribution of the anatomically and functionally
distinct adherens junctions and caveoli at the SMC plasma
membrane [26]. In order to determine if the distribution of the
PKCa and CPI-17 at the membrane corresponds with the
punctate pattern of adherens junctions, we did double labeling
with two adherens junction associated proteins, vinculin and
talin. The alternate pattern of distribution of the red and green
fluorophores at the membranes show that the PKCa and CPI-
17 do not co-localize with either vinculin or talin (Fig. 6),
suggesting that the PKCa and CPI-17 do not associate with the
adherens junction complex under the conditions we examined.
Because caveoli alternate with the adherens junctions at the
peripheral membrane [26], PKCa and CPI-17 may co-localize
with the caveoli. To determine if the punctate distribution of
the PKCa and CPI-17 at the membrane corresponds with the
punctate pattern of the caveoli, we also did double labeling of
PKCa with caveolin. The distribution of PKCa and caveolin
co-localize at the membrane in both relaxed and activated
conditions as can been observed by the appearance of the
yellow/orange fluorescence rather than distinct red and green
fluorescence (Fig. 6). A two-tailed F-test for equality of two
standard deviations (SDs) determined a significantly lower SD in
the ratio of caveolin to PKCa when compared to the SD of the
ratio of vinculin to PKCa (n = 20 cells; p,0.05). In addition,
double labeling of PKCa with CPI-17 following activation of
the tissue also shows significant co-localization (n= 20 cells;
p,0.05) of these two proteins near the plasma membrane
(fig. 7). These data show that PKCa is primarily localized near
the caveloi at the SMC plasma membrane at all times, and that
following tissue activation, a significant portion of the cytosolic
CPI-17 translocates to the caveoli at the plasma where it co-
localizes with PKCa.
Figure 2. Protein expression of CPI-17 and PKCa in fundus and antrum. A: western blot results of CPI-17 (left) and PKC (right) expression in
fundus and antrum with actin (coomassie blue stain) expression for each sample shown below. B: Quantitative data of gel/western blot results. The
expression level of CPI-17 (left) and PKCa (right) were not significantly different (p.0.23 & p.0.28 respectively, n = 6) between the fundus and
antrum.
doi:10.1371/journal.pone.0074608.g002
Figure 3. Confocal images of PKCa distribution in transverse
sections of the longitudinal and circular layer of pig stomach
fundus (left) and antrum (right) under relaxed (PSS) or
stimulated (39 CCh or 10 & 309 PDBu) treatments. Tissues were
immunoreacted for PKCa (green) and counterstained for filamentous
actin (phalloidin - red) and nuclei (DAPI - blue). In all conditions, PKCa is
located predominantly at the cell periphery near the plasma membrane.
Scale bar 210 mm.
doi:10.1371/journal.pone.0074608.g003
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Discussion
Smooth muscle tissues are routinely characterized as being
either ‘‘tonic’’ (generating a slow maintained isometric contrac-
tion) or ‘‘phasic’’ (generating a fast transient isometric contraction).
Force generation and/or tissue shortening in SM are believed to
require elevated myosin light chain phosphorylation, ATP
consumption and cross bridge cycling. A possible mechanism
responsible for these two types of contractions is differential Ca2+
sensitization. Ca2+ sensitization in smooth muscle is believed in
large part to be due to the inhibition of MLCP concurrent with or
subsequent to the activation of MLCK during tissue activation
[15,35]. One of the major pathways proposed to be involved in
Ca2+ sensitization is via G-protein coupled receptors (GPCR)/
phospholipase C (PLC)/diacylglycerol (DAG)/PKC/CPI-17 to
inhibit MLCP. GPCR’s, PLC, and DAG are all located at/in the
plasma membrane. The location of the MLCP is less certain, but
at some point in time following tissue activation MLCP needs to be
associated with MLC20 on the myosin molecule of the thick
filaments in order to dephosphorylate this protein. Because thick
filaments have been reported to be distributed throughout the
SMC cytoplasm [36,37,38,39], the MLCP will also need to be
distributed throughout the cytoplasm at some point during
relaxation [40]. If MLCP is located within the cytosol and near
MLC20 during contraction, and PKCa and CPI-17 play a role in
inhibiting MLCP during contraction, then at least CPI-17 would
be expected to be located within the cytosol at some time during
contraction. The results of this study show that PKCa is
preferentially localized near the plasma membrane during relaxed
and activated conditions and that CPI-17 is also preferentially
localized near the plasma membrane during activated conditions.
Thus, these data suggest that differences in the PKCa- CPI-17
Ca2+ sensitization pathway cannot explain tonic and phasic SM
contractions in stomach fundus and antrum and further work is
required to determine how the spatial-temporal distribution of
CPI-17 with tissue activation can regulate MLCP to cause Ca2+
sensitization of SM contraction in intact SM tissues.
While PDBu causes a slow contraction in the fundus which is
,40% of the KPSS induced peak force, little contraction is
generated in the antrum with PDBu stimulation. Since fundus and
antrum represent two basic types of smooth muscle, tonic and
phasic respectively, it seems logical to ascribe the difference in
force generation to distinct properties of phasic and tonic muscle.
Woodsome et al [41] reported that the expression level of CPI-17
in tonic vascular SM is higher than that in phasic vascular SM.
This could explain the different ability of tonic muscles to maintain
force (a high concentration of CPI-17 inhibits MLCP allowing
MLC20 phosphorylation to stay high and force to be maintained in
tonic SM). This study examined PKCa and CPI-17 protein
expression and distribution in the visceral swine stomach. To our
Figure 4. Quantitative results of the ratio of the PKCa (top panel) and CPI-17 (bottom panel) at the cells periphery to the total
protein (peripheral+cytosolic) in the circular and longitudinal layers of the antrum and fundus. The ratio of PKCa in the relaxed
condition (PSS) in both layers of antrum and fundus is significantly greater than 0.5, indicating a preferential distribution of PKCa near the plasma
membrane in the relaxed condition. This ratio does not change significantly with different stimulation treatments, suggesting that PKCa maintains a
primarily peripheral distribution in the cell at all times. (n = 5). The CPI-17 ratio in the relaxed condition (PSS) in both layers of antrum and fundus is
not significantly different than 0.5, indicating a uniform distribution of CPI-17 throughout the cells. Three minutes of CCh stimulation does not
change the ratio of CPI-17 except in the fundus circular layer. Both CCh (309) and PDBu (309) treatments cause a significantly redistribution of CPI-17
to the cell periphery near the plasma membrane (ratios are significantly greater than 0.5). * p,0.05, **p,0.01 (n = 3).
doi:10.1371/journal.pone.0074608.g004
PKCa and CPI-17 Expression in Swine Stomach
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e74608
surprise, no significant difference in the protein expression level of
PKCa or CPI-17 was detected between the fundus and antrum
(Fig. 2). These results indicate that the difference between tonic
and phasic smooth muscle in responding to varied stimulation
cannot be explained solely by differences in proteins expression of
PKCa or CPI-17 in swine stomach SM tissues.
Studies on the spatial-temporal distribution of PKC remain
controversial. Several studies suggest that PKC works as a moving
messenger to relay the cell activation signal from the membrane to
the cytosol. PKCa, a member of a large serine/threonine family of
kinases, was first identified in 1977 by Nishizuka’s group [42,43].
Castagna et al [34] who were the first to report that tumor-
promoting phorbol esters could also cause direct activation of the
Ca2+ activated, phospholipid-dependent PKC marking its signif-
icance and relevance in affecting cellular function. The first report
of PKC’s cellular localization was in EL4 mouse thymoma cells
where PKC activity was reported to be high in the cytosolic
fraction but was reduced following phorbol ester stimulation [44].
Subsequent biochemical studies in smooth muscle reported that
PKCa translocates to the membrane at different times and for
different lengths of time with different agonists [45,46,47].
Immunofluorescence microscopy, which allows direct observa-
tion of potential PKC movement within cells, shows that PKCa
undergoes a process of relocation from the cytosol to the plasma
membrane after agonist stimulation in isolated single smooth
muscle cells [48,49,50,51,52]. In contrast to these studies, there is
also evidence for movement of PKC in the opposite direction.
Fay’s group [53] reported that in isolated toad stomach single cells,
a pool of activated PKC was identified adjacent to the plasma
membrane. Upon stimulation with CCh, activated PKC (no
specific isoform mentioned) was released from the plasma
membrane associated pool and redistributed throughout the
cytosol. Further study showed that PKC became associated with
contractile filaments after the treatment [53].
To eliminate potential changes that can occur in isolated/
cultured cells compared with multicellular preparations (cell
isolation procedures disrupt cell-cell associations and alter/remove
the extracellular matrix allowing SM cytoskeletal changes) [54,55],
intact tissues were used in this study to determine the PKCa
distribution in smooth muscle cells during relaxation and
contraction. Surprisingly, the PKCa distribution was not ‘‘uni-
form’’ throughout the cell in relaxed conditions nor was it changed
upon stimulation in intact tissues. PKCa was primarily distributed
adjacent to the plasma membrane, before and after PDBu or CCh
treatment (Fig. 3). Since PKCa is a fairly large protein, it may not
be efficient to use as a moving second messenger within the cell.
CPI-17 however is a small soluble protein down-stream from
PKCa that should be able to freely diffuse throughout the SMC
until PKCa is activated and binds the CPI-17. Binding of CPI-17
by PKCa at the membrane would change the concentration of the
free CPI-17 in the subplasmalemmal region causing more CPI-17
to diffuse to the cell periphery where it also could be bound by
activated PKCa. In this way no active means of transporting CPI-
17 to the periphery would be necessary, as simple mass diffusion
due to the altered free/bound concentration of CPI-17 could
account for this ‘‘translocation’’. Our data are consistent with this,
showing a diffuse distribution of CPI-17 in SMCs under relaxed
conditions and a preferential peripheral distribution following
activation of the tissue (Fig. 4 & 5). This translocation of CPI-17
occurs in both the tonic and phasic stomach fundus and antrum
and thus cannot account for the difference in their contraction
patterns. In addition, the 3–30 minutes that it takes for the CPI-17
to show a significant translocation to the membrane appears to be
too slow to account for the early tonic force observed in tonic
muscles. This does not however exclude the possibility that this
pathway is involved in the longer maintenance of tonic force.
It is not clear what keeps the PKCa preferentially at the plasma
membrane. DAG is membrane bound and can function as a link
to PKCa at the cell membrane while it is activating PKCa.
Figure 5. Confocal images of CPI-17 distribution in transverse sections of the longitudinal and circular layer of pig stomach fundus
(left) and antrum (right) under relaxed conditions (PSS) or stimulated (309 CCh or PDBu) treatments. Tissues were immunoreacted for
CPI-17 (green) and nuclei (DAPI - blue). In relaxed condition (PSS), CPI-17 appears diffusely distributed throughout the cell. With either CCh or PDBu
stimulation, CPI-17 appears predominantly located at the periphery near the plasma membrane. Scale bar –10 mm.
doi:10.1371/journal.pone.0074608.g005
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However the accumulation of PKCa at cell periphery under
resting conditions observed in this study raises a question about the
primarily peripheral distribution of PKCa when [DAG] is
presumed to be low. Since there is no evidence to support PKCa
as a membrane embedded protein, it is necessary to speculate
other membrane associated proteins binding to PKCa under
relaxed conditions to prevent it from randomly diffusing through-
out the cell. Several proteins have been proposed to have the
ability to hold PKCa adjacent to the cell membrane. It was
reported that in cultured cells, PKCa could also be detected in
focal contact structures and might bind to talin or vinculin [56]. In
our study, double labeling of PKCa with talin or vinculin in intact
swine stomach tissues shows PKCa preferentially near the plasma
membrane but in an alternate punctate pattern with either
vinculin or talin (Fig. 6), suggesting that PKCa is not associated
with the adherens junction.
Several other studies suggest PKCa could be a resident protein
in a membrane structure called caveolae [57,58,59,60]. Studies
have identified multiple caveolae-associated proteins as having the
potential to bind to PKCa. For instance, a 68 kD PKCa binding
protein termed serum deprivation response (sdr) was localized in
caveolae [59]. It was also reported that PKCa has a particular
amino acid sequence (522WAYGVLLY528) in the catalytic
domain which has the potential of interacting with the scaffolding
domain of Caveolin-1, a resident protein in caveolae [61]. This
observation is also supported by in vitro assays suggesting caveolin-
1 has an inhibitory effect on PKCa. Sucrose gradient centrifuga-
tion showed Caveolin-1 and PKCa are accumulated in the same
fraction, which might suggest a bond between the two proteins
[62].
Several membrane receptors termed receptors for inactive/
active C-kinase isozymes (RICKs and RACKs) were also proposed
to be able to interact with inactivated or activated PKC
[21,22,63]. Their function is expected to maintain PKC in distinct
locations on or near the cell membrane. One of these scaffolding
proteins, AKAP150, has been reported to be able to target PKC to
unique plasma membrane domains where L-type Ca2+ channels
are located. The contact between PKC and Ca2+ channels was
suggested to be required for generating constitutive Ca2+ influx
[64]. This is consistent with the observation that a population of L-
type Ca2+ channels is localized to caveolae in ventricular
myocytes, since PKC was also predicted to reside in the same
location [65] and has been reported for muscarinic smooth muscle
[66]. It seems logical to propose that PKCa is anchored by
caveolin- or caveolae-associated protein(s) to the cell membrane
and activated by DAG there. Our data showing that PKCa co-
localizes with caveolin at the caveolae (Fig. 6), and in an
alternating punctate pattern with vinculin/talin, is consistent with
this idea.
The primarily peripheral distribution of CPI-17 following tissue
activation might be explained by its binding to peripherally
located, activated, PKCa. Sakai et al. examined the spatial-
temporal regulation on CPI-17 in bronchial smooth muscle of rats
under acetylcholine (ACh) stimulation [67]. Their immunoblotting
experiments revealed a time-dependent shift of CPI-17 from the
cytosolic fraction to the membrane fraction upon stimulation and
phosphorylated CPI-17 was only found in the membrane fraction,
suggesting that CPI-17 is activated at the plasma membrane [67].
Our study also revealed a punctate distribution of CPI-17 at the
membrane after stimulation (Fig. 7). The exact association of CPI-
17 at the membrane is not known at this time, but CPI-17 does co-
localize with PKCa at the caveolae. This seems logical as PKC
and CPI-17 need to be associated with each other at some point if
PKCa is going to phosphorylate CPI-17. And while CPI-17 is
observed to translocate from the cytosol to the membrane upon
stimulation (Fig. 4 & 5), there is still a significant amount of CPI-17
remaining in the cytosol following tissue activation (Fig. 4 & 5 and
[68]). Kolosova et al. [68] reported that the distribution of CPI-17
was parallel with actin in human pulmonary artery endothelial cell
suggesting a co-localization of CPI-17 and actin. Thus it is possible
that when CPI-17 is in the cytosol, it associates with actin
filaments, though we saw no evidence for this in our tissues.
Moreover, a certain amount of CPI-17 has been reported to be
located adjacent to the nucleus [69]. This may be explainable by
Figure 6. Confocal images of pig fundus (upper panel) in
relaxed condition (top row) and with PDBu (309) stimulation
(lower row). Double labeling for PKCa (green) with vinculin (red,
upper left) or talin (red, upper right) or CPI-17 (green) with vinculin (red,
lower left) or talin (red, lower right). Vinculin and talin are adherens
junction associated proteins that appear to have an alternating
distribution with PKC and CPI-17, suggesting that these proteins are
not localized to the same domains near the plasma membrane. Note
that not all of the PKCa or CPI-17 is located near the plasma membrane.
Lower panel - Relaxed (PSS – upper row) and activated (PDBu – lower
row) pig antrum tissue reacted with PKCa (left column, green) and
caveolin (middle column, red) and merged with nuclei (right column,
PKCa – green; caveolin – red; DAPI – blue). Co-localization of PKCa and
caveolin result in yellow/orange fluorescence. Scale bar = 10 mm.
doi:10.1371/journal.pone.0074608.g006
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reports that PKCa can localize to the perinuclear region in
vascular smooth muscle cells [70].
Our data show that the translocation of CPI-17 to the
membrane is a very slow process requiring greater than 3 min
for a significant shift (Fig. 4) and that it remains preferentially
localized near the plasma membrane following 30 min of
stimulation with either CCh or PDBu. Sakai et al [67] reported
that it takes two minutes following ACh stimulation for CPI-17 to
translocate to the membrane fraction in rat bronchial SM and that
it remains there as long as the tissue is stimulated (.20 minutes).
They also reported the presence of phosphorylated CPI-17 follows
a slightly slower time frame, becoming significant in the
membrane fraction at ten minutes. Phosphorylated CPI-17 was
not observed in the cytosolic fraction, and only decreased in
concentration following relaxation of the tissue. Thus our data
(fig. 4) and that from [67] suggests that CPI-17 (p-CPI-17) does not
return to the cytosol (cytosolic fraction for Sakai) while the tissue is
activated.
The failure of CPI-17 (p-CPI-17, [67]) to return to the cytosol
during activation of SM tissue leaves a gap in the PKC/CPI-17/
MLCP pathway for Ca2+ sensitization via inactivation of MLCP.
While CPI-17 (p-CPI-17, ref [67]) is primarily localized near the
plasma membrane following activation of smooth muscle tissues
[67] the MLC20 is distributed throughout the cell as part of the
thick filament myosin protein. MLCP needs to be associated with
myosin if it is going to dephosphorylate MLC20, and it needs to be
associated with CPI-17 if it is going to be inhibited from
dephosphorylating MLC20. There are a number of possible
explanations to address this. The first would be that there is
another currently unidentified protein(s) in this pathway that is
activated by CPI-17 and is responsible for inhibiting MLCP. This
seems unlikely based on publications showing a direct inhibitory
effect of CPI-17 on MLCP [71]. A second possibility would be that
CPI-17 is not involved in Ca2+sensitization in intact visceral SM
tissues, or perhaps not in specific SM tissues (stomach and
bronchial). This seems equally unlikely as there are reports of this
pathway being relevant in the gut and airway [17,67]. A third
possible explanation would be that MLCP actually translocates to
the periphery by mass action following the shift in distribution of
CPI-17. It could be inactivated by CPI-17 at the periphery, or
merely no longer effective as a MLC20 phosphatase because it is
no longer associated with MLC20 on the thick filaments located in
the cytosol [40,72]. This last explanation seems to warrant further
testing.
This leads us to propose the following model for Ca2+
sensitization via the PKC/CPI-17/MLCP pathway. In intact
visceral (and other?) smooth muscle tissues, PKCa is localized
primarily at the plasma membrane by binding to RICKs [21].
With tissue activation, an increase in plasma membrane DAG
activates PKCa at the membrane. CPI-17 is bound by the
activated membrane bound PKCa, causing a shift in its
distribution from diffusely distributed throughout the cytosol to
primarily at the plasma membrane. Activated PKCa activates the
bound CPI-17 (p-CPI-17) which remains at the membrane until
the activating stimulus is removed and the tissue relaxes. How the
MLCP is inhibited, and whether it moves within the cell remains
unresolved. We hypothesize that the p-CPI-17 binds to MLCP at
the plasma membrane. This would have two consequences. The
first is that there would be a shift in distribution of MLCP from the
cytosol to the plasma membrane (we were unable to test this as no
MLCP antibodies could be obtained that worked in the swine
tissue). The second consequence would be that by shifting the
distribution of MLCP away from myosin (MLC20) to the plasma
membrane, MLCP would be ineffective in de-phosphorylating
MLC20. This would explain the Ca
2+ sensitization by keeping
MLC20 phosphorylation levels elevated and enhancing tissue force
during the extended period of time the tissue is stimulated.
A remaining unresolved issue is the different responses of the
tonic fundus and phasic antrum to PDBu stimulation. One
possibility is that the different responses to PDBu are caused by
differences in basal Ca2+ level between tonic and phasic smooth
muscle. It was reported that tonic tissues have a higher level of
[Ca2+]i than phasic tissues under relaxed conditions [73]. It is
possible that although PDBu administration could boost Ca2+
sensitization in phasic smooth muscle to a similar level as in tonic
tissues, the low basal level of [Ca2+]i might still not be able to
maintain a strong contraction in phasic tissues. The differences of
sarcoplasmic reticulum distribution in the two types of tissues may
be responsible for differences in the [Ca2+]i in basal conditions
[74]. A second possibility could be that expression patterns of
MLCP are different between tonic and phasic smooth muscle and
this difference leads to differences in contraction to PDBu
stimulation. This is supported by the observation that phasic
smooth muscle contains more MLCP than tonic tissues [41]. The
above explanations are not necessarily exclusive to each other and
the cause for differences in force generation between tonic and
phasic SM may be the combination of the two, and further study is
needed to address these issues. In addition, there are numerous
other second messenger pathways reported to affect MLCP
activity including RhoA/ROCK, ILK, and Zip kinase, [18] and
these undoubtedly are also important and need to be tested. While
the entire mechanism remains unresolved, this study shows there
are no differences in PKCa and CPI-17 protein expression or
distribution that can explain the sustained tonic vs. transient
Figure 7. Pig antrum activated with PDBu and reacted with PKCa (left column, green) and CPI-17 (middle column, red) and merged
with nuclei (right column, PKCa – green; CPI-17– red; DAPI – blue). Co-localization of PKCa and CPI-17 result in yellow/orange fluorescence.
Scale bar = 10 mm.
doi:10.1371/journal.pone.0074608.g007
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phasic contractions observed in intact stomach fundus and antrum
smooth muscle.
Supporting Information
Figure S1 Representative confocal Z-stack series of
CPI-17 distribution in transverse section of the circular
layer of pig antrum in relaxed conditions (PSS). Tissues
were immunoreacted for CPI-17 (green). CPI-17 appears diffusely
distributed throughout the cell regardless of the level of the Z-stack
section in relaxed conditions.
(TIF)
Figure S2 Representative confocal Z-stack series of
CPI-17 distribution in transverse section of the circular
layer of pig antrum following 30 minutes stimulation in
1 mM PBDu. Tissues were immunoreacted for CPI-17
(green). With PDBu stimulation, CPI-17 appears predominantly
located at the periphery near the plasma membrane regardless of
the level of the Z-stack section.
(TIF)
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